{"pmid":32147378,"title":"COVID-19 and Blood Safety: Help with a Dilemma.","text":["COVID-19 and Blood Safety: Help with a Dilemma.","Transfus Med Rev","Dodd, Roger Y","Stramer, Susan L","32147378"],"journal":"Transfus Med Rev","authors":["Dodd, Roger Y","Stramer, Susan L"],"date":"2020-03-10T11:00:00Z","year":2020,"_id":"32147378","week":"202011|Mar 09 - Mar 15","doi":"10.1016/j.tmrv.2020.02.004","source":"PubMed","weight":0,"_version_":1661359647802523650,"score":6.7365713,"similar":[{"pmid":32107119,"title":"Coronavirus Disease 2019: Coronaviruses and Blood Safety.","text":["Coronavirus Disease 2019: Coronaviruses and Blood Safety.","With the outbreak of unknown pneumonia in Wuhan, China, in December 2019, a new coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), aroused the attention of the entire world. The current outbreak of infections with SARS-CoV-2 is termed Coronavirus Disease 2019 (COVID-19). The World Health Organization declared COVID-19 in China as a Public Health Emergency of International Concern. Two other coronavirus infections-SARS in 2002-2003 and Middle East Respiratory Syndrome (MERS) in 2012-both caused severe respiratory syndrome in humans. All 3 of these emerging infectious diseases leading to a global spread are caused by beta-coronaviruses. Although coronaviruses usually infect the upper or lower respiratory tract, viral shedding in plasma or serum is common. Therefore, there is still a theoretical risk of transmission of coronaviruses through the transfusion of labile blood products. Because more and more asymptomatic infections are being found among COVID-19 cases, considerations of blood safety and coronaviruses have arisen especially in endemic areas. In this review, we detail current evidence and understanding of the transmission of SARS-CoV, MERS-CoV, and SARS-CoV-2 through blood products as of February 10, 2020, and also discuss pathogen inactivation methods on coronaviruses.","Transfus Med Rev","Chang, Le","Yan, Ying","Wang, Lunan","32107119"],"abstract":["With the outbreak of unknown pneumonia in Wuhan, China, in December 2019, a new coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), aroused the attention of the entire world. The current outbreak of infections with SARS-CoV-2 is termed Coronavirus Disease 2019 (COVID-19). The World Health Organization declared COVID-19 in China as a Public Health Emergency of International Concern. Two other coronavirus infections-SARS in 2002-2003 and Middle East Respiratory Syndrome (MERS) in 2012-both caused severe respiratory syndrome in humans. All 3 of these emerging infectious diseases leading to a global spread are caused by beta-coronaviruses. Although coronaviruses usually infect the upper or lower respiratory tract, viral shedding in plasma or serum is common. Therefore, there is still a theoretical risk of transmission of coronaviruses through the transfusion of labile blood products. Because more and more asymptomatic infections are being found among COVID-19 cases, considerations of blood safety and coronaviruses have arisen especially in endemic areas. In this review, we detail current evidence and understanding of the transmission of SARS-CoV, MERS-CoV, and SARS-CoV-2 through blood products as of February 10, 2020, and also discuss pathogen inactivation methods on coronaviruses."],"journal":"Transfus Med Rev","authors":["Chang, Le","Yan, Ying","Wang, Lunan"],"date":"2020-02-29T11:00:00Z","year":2020,"_id":"32107119","week":"20209|Feb 24 - Mar 01","doi":"10.1016/j.tmrv.2020.02.003","keywords":["2019-nCoV","Blood safety","COVID-19","Coronavirus","MERS","Pathogen inactivation technology","SARS","SARS-CoV-2"],"source":"PubMed","locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Transmission"],"weight":1,"_version_":1661359647485853696,"score":43.72344}]}